ArticleBMC ophthalmology2026
Impact of combined Hydrus Microstent implantation and cataract surgery on diurnal intraocular pressure range: a longitudinal, retrospective study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of combined Hydrus Microstent implantation and cataract surgery on the 24-hour intraocular pressure (IOP) range in patients with open-angle glaucoma. PATIENTS AND
methodsThis retrospective, single-center study included 125 consecutive eyes of 125 patients who underwent combined Hydrus Microstent implantation and cataract surgery. Inpatient 24-hour IOP profiles (comprising daytime Goldmann applanation tonometry and nocturnal iCare rebound tonometry) from before and after surgery were analyzed. Surgical success was defined as a postoperative mean 24-hour IOP ≤ 21 mmHg with either a ≥ 20% reduction from baseline or a reduction in glaucoma medication burden. The primary outcome measures were changes in mean 24-hour IOP, maximum 24-hour IOP, and 24-hour IOP range (defined as the difference between the maximal and minimal 24-hour IOP).
resultsMean preoperative 24-hour IOP of 21.0 ± 5.5 mmHg decreased to 16.5 ± 4.0 mmHg postoperatively (mean reduction: 4.5 mmHg) at a mean follow-up of 76 days (range 7-338 days; median 61 days; IQR 35-91). The 24-hour IOP range significantly decreased from 10.7 ± 6.5 mmHg to 7.7 ± 4.0 mmHg (p < 0.001), and mean maximum 24-hour IOP decreased by 6.2 ± 5.4 mmHg. The number of glaucoma medications was reduced from 2.4 ± 1.2 to 0.6 ± 1.1, with 74.4% of patients becoming medication-free. Overall surgical success was achieved in 88.0% of patients.
conclusionCombined Hydrus Microstent implantation and cataract surgery significantly reduced glaucoma medication burden and effectively decreased 24-hour IOP range and pressure spikes. PRéCIS: Combined Hydrus Microstent implantation with cataract surgery reduced diurnal intraocular pressure range and pressure peaks while lowering mean intraocular pressure, indicating improved pressure stability beyond average reduction alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.